Regulation of Hematopoietic Stem Cell Engraftment by the Endothelial Cell Niche
Background
Allogeneic hematopoietic stem cell transplantation (HSCT), or bone marrow transplantation, is the most aggressive treatment available for children with high-risk or relapsed leukemia. Despite this aggressive treatment, half of the children who receive HSCT will ultimately die of their disease or the side effects of transplantation. Consequently it is important for us to identify new ways to improve the safety and efficacy of HSCT.
Children who receive allogeneic HSCT are treated with high doses of chemotherapy and radiation followed by intravenous infusion of hematopoietic stem cells (HSCs) from another individual. Circulating HSCs home to the bone marrow, engraft within a microenvironment formed by cells lining the marrow blood vessels, and then establish a new blood system. HSCs are guided to the microenvironment by chemoattractants and cellular adhesion molecules. Once there, the HSCs compete for growth factors and other resources with residual leukemia cells that have survived the conditioning regimen.
Project Goals
Using a genetic screen in the developing zebrafish, I have identified one molecule which is important for normal HSC engraftment. This proposal aims to understand the biology of this factor and to identify other secreted growth factors and chemoattractants that the microenvironment uses to regulate the activity of HSCs. Secreted factors are attractive candidates for drug development and may provide the key to improving outcomes for children who receive HSCT for high-risk leukemia. Promising candidates will be carried forward for additional translational and clinical studies in concert with the Boston Children's Hospital Stem Cell Transplantation Program.

